Canaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by stock analysts at Canaccord Genuity Group from $74.00 to $54.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Other research analysts also recently issued research reports about the […]
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by stock analysts at Canaccord Genuity Group from $74.00 to $54.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Other research analysts also recently issued research reports about the […]
